✦ LIBER ✦

Safety and Efficacy of Intravenous Recombinant Tissue Plasminogen Activator Administered in the 3- to 4.5-hour Window in Korea

✍ Scribed by Park, Tai Hwan; Lee, Ji Sung; Park, Sang-Soon; Ko, Youngchai; Lee, Soo Joo; Lee, Kyung Bok; Lee, Jun; Kang, Kyusik; Park, Jong-Moo; Choi, Jay Chol; Kim, Dong-Eog; Cho, Yong-Jin; Kim, Joon-Tae; Kim, Dae-Hyun; Cha, Jae-Kwan; Han, Moon-Ku; Lee, Juneyoung; Oh, Mi Sun; Yu, Kyung-Ho; Lee, Byung-Chul; Bae, Hee-Joon; Hong, Keun-Sik

Book ID: 125823286
Publisher: Elsevier Science
Year: 2014
Tongue: English
Weight: 535 KB
Volume: 23
Category: Article
ISSN: 1532-8511
DOI: 10.1016/j.jstrokecerebrovasdis.2014.04.027

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The safety and efficacy of the intraveno

The safety and efficacy of the intravenous recombinant tissue plasminogen activator for the ischemic stroke patients in community based hospital

✍ Joung, J.; Song, I.U.; Joung, D. 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 60 KB

Efficacy and Safety of a Modified Intrav

Efficacy and Safety of a Modified Intravenous Recombinant Tissue Plasminogen Activator Regimen in Chinese Patients with Acute Ischemic Stroke

✍ Pan, Shu-Ming; Liu, Jia-Fu; Liu, Ming; Shen, Sa; Li, Hao-Jun; Dai, Li-Hua; Chen, 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 184 KB

Safety and efficacy of a new regimen of

Safety and efficacy of a new regimen of intravenous recombinant tissue-type plasminogen activator potentially suitable for either prehospital or in-hospital administration

✍ George R. McKendall; Michael J. Attubato; Thomas M. Drew; Frederick Feit; Barry 📂 Article 📅 1991 🏛 Elsevier Science 🌐 English ⚖ 301 KB

Reply to ‘Comment on “Efficacy and safet

Reply to ‘Comment on “Efficacy and safety of different doses of intravenous tissue plasminogen activator in Chinese patients with ischemic stroke”’

✍ Xiao-Yu Zhou; Bernard Yan 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 31 KB

A randomized trial confirming the effica

A randomized trial confirming the efficacy of reduced dose recombinant tissue plasminogen activator in a Chinese myocardial infarction population and demonstrating superiority to usual dose urokinase: The TUCC trial

✍ Allan M. Ross; Runlin Gao; Karin S. Coyne; Jilin Chen; Kangbao Yao; Yuejin Yang; 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 79 KB

A randomized controlled trial evaluating

A randomized controlled trial evaluating the efficacy and safety of intermittent 3-, 4-, and 5-day cycles of intravenous recombinant human Interleukin-2 combined with antiretroviral therapy (ART) versus ART alone in HIV-seropositive patients with 100–300 CD4+ t cells

✍ Alberdina W de Boer; Norman Markowitz; H.Clifford Lane; Louis D Saravolatz; Susa 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 109 KB